In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.
News|Podcasts|August 13, 2026
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why protocol training completion doesn't ensure site execution readiness, how AI clinical monitoring drives measurable financial returns, and structural compliance failures behind rising FDA warning letters.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new episode of Beyond Compliance , Joseph Kim, Chief Strategy Officer at ProofPilot, and Lauren Briggs, Chief Customer Officer at ProofPilot, discussed why training completion records don't reflect whether site staff can execute a specific visit. Role-based, visit-by-visit guidance delivered just in time improves protocol adherence more effectively than one-time comprehensive courses. - A
Tufts CSDD analysis quantified the financial value of deploying an AI clinical monitoring agent across oncology programs, finding expected net present value gains of $21 million for Phase III trials and ROI multiples as high as 82x. Direct monitoring cost reductions totaled $5.6 million per Phase III study, with accelerated enrollment timelines reducing timelines by 109 to 119 days and database lock by two weeks. - In a
Q&A from Pharmaceutical Executive , Joseph Morwald, founder and CEO of Krieger Scientific, discussed why FDA warning letters jumped 59%, reaching 303 in 2025, pointing to siloed systems and over-reliance on AI without adequate human review as structural causes. The agency has emphasized that human oversight must verify any AI-generated documentation or data before submission, since organizations cannot catch problems when validation and quality functions operate in fragmented silos.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
Trending on Applied Clinical Trials Online
1
Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development
2
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
3
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
4
ACT Brief: Patient-Site Interaction and Technology, AI Pilot Success Requires Discipline, and CagriSema Beats Lilly Drug
5